

**AMENDMENTS TO THE CLAIMS**

1. **(Currently Amended)** Use A method for the treatment of a tumor, which comprises administering to a patient in need of such treatment and effective amount of active dendritic cells (DCs) releasing interleukin 12 (IL-12) which are loaded with an antigen against a specific tumor and, due to the treatment with lipopolysaccharide (LPS) and interferon-gamma (IFN- $\gamma$ ), release IL-12, for the preparation of a medicament for treating a patient having said specific tumor.
2. **(Currently Amended)** Use The method according to claim 1, characterised in that wherein said treatments is performed after bone marrow transplantation.
3. **(Currently Amended)** Use The method according to claim 1, characterised in that wherein said specific tumor is an advanced malignancy.
4. **(Currently Amended)** Use The method according to claim 1, characterised in that in wherein said DCs are DCs having been taken from the patient having said specific tumor or from the bone marrow donor.
5. **(Currently Amended)** Use The method according to claim 1, characterised in that wherein the DCs have been loaded with an antigen from a tumor cell from said patient having said specific tumor.
6. **(Currently Amended)** Use The method according to claim 5, characterised in that wherein the DCs are additionally charged with a tracer antigen.
7. **(Currently Amended)** Use The method according to claim 6, characterised in that wherein said tracer antigen is keyhole limpet hemocyanine (KLH).
8. **(Currently Amended)** Use The method according to claim 7, characterised in that wherein the DCs are additionally charged with an adjuvant, especially with tetanus toxoid.

9. **(Currently Amended)** Use The method according to claim 1, characterised in that wherein the DCs have been generated in vitro from peripheral blood mononuclear cells (PBMCs).

10. **(Currently Amended)** Composition A composition for triggering IL-12 release from DCs containing which comprises LPS, IFN- $\gamma$  and a tumor antigen.

11. **(Currently Amended)** Composition The composition according to claim 10, characterised in that it wherein the composition is calf-serum free.

12. **(Currently Amended)** Use A method for triggering IL-12 release from dendritic cells (DCs) which comprises administering to a patient an effective amount of a combination of LPS, IFN- $\gamma$  and a tumor antigen for triggering IL-12 release from DCs.

13. **(Currently Amended)** Use The method according to claim 12, characterised in that wherein the DCs have been loaded with an antigen from a tumor cell from a patient having said tumor.

14. **(Original)** Kit for triggering IL-12 release from DCs comprising

- LPS,
- IFN- $\gamma$  and
- a tumor antigen.

15. **(Currently Amended)** Use of a kit according to claim 14 A method for for triggering IL-12 release from dendritic cells (DCs) which comprises exposing DCs to the kit of claim 14.

16. **(Currently Amended)** Use The method according to claim 15, characterised in that wherein the DCs have been loaded with an antigen from a tumor cell from a patient having ~~said a~~ tumor.